Heidelberg Pharma AG (XTER:HPHA) Other Income (Expense) : €8.84 Mil (TTM As of May. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Other Income (Expense)?

Heidelberg Pharma AG's other income expense for the Heidelberg Pharma AG's pretax income for the three months ended in May. 2024 was €1.64 Mil. Its other income expense for the trailing twelve months (TTM) ended in May. 2024 was €8.84 Mil.

Heidelberg Pharma AG Other Income (Expense) Historical Data

The historical data trend for Heidelberg Pharma AG's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Other Income (Expense) Chart

Heidelberg Pharma AG Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Other Income (Expense)

Get a 7-Day Free Trial

0.22

0.21

0.15

1.22

6.89

Heidelberg Pharma AG Quarterly Data
	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24
Other Income (Expense)	Get a 7-Day Free Trial															0.18	6.98	-0.37	0.59	1.64

Heidelberg Pharma AG Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.84 Mil.

Heidelberg Pharma AG (XTER:HPHA) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Heidelberg Pharma AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Executives

Prof. Dr. Andreas Pahl

Board of Directors

Heidelberg Pharma AG Headlines

No Headlines